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A B ST R AC T  
 
Aim: To evaluate the risk factors in patients with pancreatic adenocarcinoma in Turkey's Black Sea region and 
to determine groups at high risk for pancreatic cancer. 
Methods: 106 newly diagnosed pancreatic adenocarcinoma patients living in Black Sea region of Turkey who 
applied to our clinic between January 2015 and December 2016 were included in this study. In the same period 
a control group was formed with 92 patients of similar age. Both groups were asked to fill out a form that 
questioned the pancreatic cancer risk factors. Data were analyzed. 
Results: Pancreatic cancer risk was 3.5 times higher in people over 65 years of age. Patients with deficient 
level of serum vitamin D level (<20 ng/ml) had 10.2 times more risk of pancreatic cancer than patients with 
normal level of Vitamin D (≥30 ng/ml). While newly diagnosed type 2 diabetics had 19.5 times higher risk of 
pancreatic cancer, long term type 2 diabetics had 1.2 times higher risk than normal individuals. Those with 
pancreatic cancer in family had 4.3 times higher risk than those who did not. It was observed that people with 
rhesus (Rh) antigen negative blood group has 70% less risk of pancreatic cancer.  
Conclusion: Determination of pancreatic cancer risk factors, organization of imaging and screening programs 
for high-risk people can provide early diagnosis of the disease and prolong survival. 
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Introduction 
Although pancreatic cancer is the 11th most 
common cancer type, it ranks as the third 
leading cause of cancer-related death in the 
USA [2]. Pancreatic cancer is predicted to be 
the second most common cause of cancer-
related deaths in coming 20 years [3]. In a study 
conducted by Parkin et al. in 2002, pancreatic 
cancer accounts for 3% of all cancer types 
worldwide, however, it is among the top in 
cancer-related deaths due to its poor diagnosis 
[1]. In many patients, when pancreatic cancer is 
detected, the disease is advanced and the tumor 
is not operable. Median survival rate is less than 
a year, and mortality rate is approximately 99%. 
Only less than 10% of pancreatic tumors can be 
detected at an early phase and resected. Usually 
the disease starts to develop two years before its 
diagnosis [4]. Most patients initially have a 
non-specific pain in epigastrium. As the disease 
develops in time, the pain spreads over to the 
back, upper thoracic and lumbar region. Upon 
progress of the disease, most patients consult 
doctors with complaints of pain, jaundice, and 
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loss of weight. It is often the case that when 
patient seeks medical advice with these 
complaints, the disease has already reached the 
advanced stage [1-5]. 
There are numerous studies conducted to 
identify causes of pancreatic cancer. In 
etiology, environmental and genetic causes are 
considered to play a joint role. Risk factors are 
divided in two as changeable and unchangeable 
risk factors. Unchangeable risk factors are age, 
gender, race, genetic factors, family history, 
atopy/allergy history, blood groups, surgery 
history, diabetes and chronic pancreatitis. 
Changeable risk factors, on the other hand, can 
be listed as smoking, obesity, use of alcohol, 
dietary, socio-economic conditions, infections, 
levels of vitamin D and folic acid. Analysis of 
risk factors and identification of factors that 
significantly increases the risk are of high 
importance [1-10]. Identifying populations of 
high-risk, establishing imaging and screening 
programs for these groups can support early 
diagnosis of the disease and increase survival 
period.  Therefore, in this study, we aimed to 
identify high-risk groups together with risk 
factors in patients with pancreatic 
adenocarcinoma in Turkey's Black Sea region. 
 
Materials and Methods 
Ethical approval for this study was obtained 
from the local ethics committee (IRB approval 
number 144/2015). Necessary permissions 
were obtained from the hospital and families. 
All procedures performed in studies involving 
human participants were in accordance with the 
ethical standards of the institutional and/or 
national research committee and with the 1964 
Helsinki declaration and its later amendments 
or comparable ethical standards. 
106 newly diagnosed pancreatic 
adenocarcinoma patients living in Black Sea 
Region of Turkey who applied to our clinic 
between January 2015 and December 2016 
were included in this study. In the same period, 
a control group was also formed with 92 
patients of similar age group who visited our 
clinic for another disease and had not been 
diagnosed with cancer. Both groups were asked 
to fill out a form that questioned the risk factors. 
The factors to be investigated in this study, 
conducted as a case-controlled and cross-
sectional study, are defined as follows: age 
(≤50, 51-65, >65); gender (female, male); 
family history of pancreatic cancer (yes, no); 
atopy/allergy (yes, no); blood type (A,B,O,AB; 
rhesus (Rh) antigen negative, Rh antigen 
positive); cholecystectomy (yes, no); 
gastrectomy (yes, no); type 2 diabetes (yes, no); 
duration of diabetes - newly diagnosed type 2 
diabetes (<2 years), long term type 2 diabetes 
(≥2 years); smoking (never smoked, still 
smoking or stopped smoking); body mass index 
(BMI) normal weight (18.5-24.99), pre-obesity 
(25-29.99), obesity (≥30); alcohol consumption 
(yes, no); place of residence (rural, urban); 
helicobacter pylori history (yes, no); level of 
vitamin D normal (>30, 80 ng/ml), insufficient 
(20, ≤30 ng/ml), deficient (<20 ng/ml); level of 
folic acid  low (<4.6 ng/ml), normal (4.6-18.7 
ng/ml), high (>18.7 ng/ml).  
Statistical analysis 
The collected data were analyzed with IBM 
SPSS V23. In the evaluation of the study data, 
besides the descriptive statistical methods 
(mean, standard deviation), in the comparison 
of qualitative data; Pearson's chi-squared test 
were used. The p-value <0.05 was significantly 
considered. Independent Sample T-test was 
applied in the analysis of the significance of the 
difference between the averages obtained. 
 
Results  
There was no significant difference across 
groups concerning age and gender (p>0.05) 
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(see Table 1). Pancreatic cancer risk was found 
3.5 times higher in patients over 65 years of age 
compared to the control group (p<0.05). 
Gender was not associated with increased 
pancreatic cancer risk (p>0.05). The risk of 
pancreatic cancer was observed 3.4 times 
higher in people with insufficient serum 
vitamin D level. For people with deficient level 
of serum vitamin D, the risk increased 10.2 
times more (p<0.05). When non-smokers were 
taken as reference, there was no increase in the 
risk of pancreatic cancer in individuals who quit 
smoking or who are smoking (p>0.05). The risk 
of pancreatic cancer was detected to increase 
1.2-fold in diabetic patients (p<0.05). When 
diabetic patients were classified as newly 
diagnosed type 2 diabetes (<2 years) and long-
term type 2 diabetes (≥2 years), the risk of 
pancreatic cancer increased by 19.5-fold in 
newly diagnosed type 2 diabetic patients 
(p<0.05). There was no association between 
BMI, alcohol use, chronic pancreatitis and 
pancreatic cancer risk (p>0.05). Compared to 
the control group, the risk of pancreatic cancer 
was observed to increase 4.3-fold in patients 

















There was no significant difference in terms of 
pancreatic cancer risk between those living in 
urban areas and rural areas (p>0.05). Similarly, 
we observed no relation between the level of 
serum folic acid, distribution of ABO blood 
types, helicobacter pylori, atopy/allergy, 
gastrectomy, cholecystectomy, and the risk of 
pancreatic cancer (p>0.05). However, the risk 
of pancreatic cancer was found less patients 
with Rh antigen negative blood group (p<0.05) 
(See table 2). 
There was no significant difference across 
groups concerning age and gender (p>0.05) 
(See Table 1). Pancreatic cancer risk was found 
3.5 times higher in patients over 65 years of age 
compared to the control group (p<0.05). 
Gender was not associated with increased 
pancreatic cancer risk (p>0.05). The risk of 
pancreatic cancer was observed 3.4 times 
higher in people with insufficient serum 
vitamin D level. For people with deficient level 
of serum vitamin D, the risk increased 10.2 
times more (p<0.05). When non-smokers were 
taken as reference, there was no increase in the 
risk of pancreatic cancer in individuals who quit 
smoking or who are smoking (p>0.05). The risk 
















   Table 1. Age and gender distribution. 






Average age (Years) 65 ±11 62 ±13 0.207 
Age groups   ≤50 
                      51-65 
                      >65 
11 (10.4%) 19 (20.7%) 
0.052 33 (31.1%) 33 (35.9%) 
62 (58.5%) 40 (43.5%) 
Gender        Male 
                     Female 
63 (59.4%)                        52 (56.5%) 
0.679 
43 (40.6%) 40 (43.5%) 
 
                                              Derebey et al / Exp Biomed Res. 2021; 4(1):38-46 
























































































  Table 2. Comparison of pancreatic cancer risk factors between groups. 
Parameters Pancreatic Cancer 
Group 
Control Group  
  
OR  P 
Age groups     
  ≤50 
  51-65 
  >65 
11 (10.4%) 19 (20.7%) Reference 
0.014 33 (31.1%) 33 (35.9%) 1.3 (0.4 – 4.1) 
62 (58.5%) 40 (43.5%) 3.5 (1.2 – 10.2) 
Gender     
  Male 
  Female 
63 (59.4%) 52 (56.5%) Reference 
0.616 
43 (40.6%) 40 (43.5%) 0.9 (0.4 – 2.2) 
Serum vitamin D level (ng/ml)     
  Normal (>30, 80) 
  Insufficient (20, ≤30) 
  Deficient (<20) 
3 (2.8%) 10 (10.9%) Reference 
0.001 6 (5.7%) 15 (16.3%) 3.4 (0.5 – 25.4) 
97 (91.5%) 67 (72.8%) 10.2 (2 – 52.6) 
Smoking     
  Never smoked 
  Still smoking or smoked   before/quit smoking 
51 (48.1%) 52 (56.5%) Reference 
0.242 
55 (51.9%) 40 (43.5%) 1.6 (0.7 – 3.8) 
Body mass index (kg/m2)     
  Normal (18.5-24.99) 
  Pre-obesity (25-29.99) 
  Obesity (≥30) 
22 (20.8%) 28 (30.4%) Reference 
0.757 44 (41.5%) 32 (34.8%) 1.7 (0.7 – 4.3) 
40 (37.7%) 32 (34.8%) 1.3 (0.5 – 3.6) 
Type 2 diabetes     
  No 
  Yes 
65 (61.3%) 73 (79.3%) Reference 
0.001 
41 (38.7%) 19 (20.7%) 1.2 (0.4 – 3.1) 
Duration of type 2 diabetes (years) 
  No 
  Newly diagnosed type 2 diabetes (<2 years) 
  Long term type 2 diabetes (≥2 years) 
65 (61.3%) 73 (79.3%) Reference 
0.003 23 (21.7%) 2 (2.2%) 19.5(3 – 127.3) 
18 (17.0%) 17 (18.5%) 1.2 (0.6 – 2.5) 
Family history of pancreatic cancer 
  No 
  Yes 
96 (90.6%) 89 (96.7%) Reference 
0.041 
10 (9.4%) 3 (3.3%) 4.3 (0.8 – 22.3) 
Alcohol consumption 
  No 
  Yes 
88 (83.0%) 77 (83.7%) Reference 
0.796 
18 (17.0%) 15 (16.3%) 0.9 (0.3 – 2.6) 
Place of residence 
  Rural 
  Urban 
50 (47.2%) 27 (29.3%) 2 (0.9 – 4.3) 
0.054 
56 (52.8%) 65 (70.7%) Reference 
Chronic pancreatitis history 
  No 
  Yes 
104 (98.1%) 91 (98.9%)  Reference 
0.814 
2 (1.9%) 1 (1.1%) 0.7 (0.1 – 32.4) 
Helicobacter pylori history 
  No 
  Yes 
93 (87.7%) 85 (92.4%) Reference 
0.310 
13 (12.3%) 7 (7.6%) 1.5 (0.5 – 5.3) 
Serum folic acid level (ng/ml)     
  Low (0, <4.6) 
  Normal (4.6-18.7) 
  High (>18.7) 
9 (8.5%) 18 (19.6%) Reference 
0.099 91 (85.8%) 69 (75.0%) 3.7 (1.2 – 11.5) 
6 (5.7%) 5 (5.4%) 2.8 (0.5 – 15.1) 
Blood groups 
  O 
  A 
  B 
  AB 
30 (28.3%) 32 (34.8%) Reference 
0.835 
56 (52.8%) 36 (39.1%) 1.5 (0.7 – 3.4) 
14 (13.2%) 19 (20.7%) 0.6 (0.2 – 1.8) 
6 (5.7%) 5 (5.4%) 1.1 (0.2 – 5.4) 
Rh status 
  Rh antigen negative  
  Rh antigen positive  
91 (85.8%) 69 (75.0%) Reference 
0.006 
15 (14.2%) 23 (25.0%) 0.3 (0.1 – 0.8) 
Atopy/allergy 
  No 
  Yes 
99 (93.4%) 82 (89.1%) Reference 
0.453 
7 (6.6%) 10 (10.9%) 0.6 (0.1 – 2.3) 
Cholecystectomy 
  No 
  Yes 
91 (85.8%) 83 (90.2%) Reference 
0.466 
15 (14.2%) 9 (9.8%) 1.6 (0.5 – 5.3) 
Gastrectomy 
  No 
  Yes 
102 (96.2%) 90 (97.8%) Reference 
0.926 4 (3.8%) 2 (2.2%) 1.1 (0.2 – 8.2) 
 
                                              Derebey et al / Exp Biomed Res. 2021; 4(1):38-46 




1.2-fold in diabetic patients (p<0.05). When 
diabetic patients were classified as newly 
diagnosed type 2 diabetes (<2 years) and long-
term type 2 diabetes (≥2 years), the risk of 
pancreatic cancer increased by 19.5-fold in 
newly diagnosed type 2 diabetic patients 
(p<0.05). There was no association between 
BMI, alcohol use, chronic pancreatitis and 
pancreatic cancer risk (p>0.05). Compared to 
the control group, the risk of pancreatic cancer 
was observed to increase 4.3-fold in patients 
with pancreatic cancer history in the family 
(p<0.05). There was no significant difference 
in terms of pancreatic cancer risk between those 
living in urban areas and rural areas (p>0.05). 
Similarly, we observed no relation between the 
level of serum folic acid, distribution of ABO 
blood types, helicobacter pylori, atopy/allergy, 
gastrectomy, cholecystectomy, and the risk of 
pancreatic cancer (p>0.05). However, the risk 
of pancreatic cancer was found less patients 
with Rh antigen negative blood group (p<0.05) 
(see Table 2). 
 
Discussion 
In the United States, 10% of pancreatic cancers 
are under the age of 50. It has been reported that 
the risk of cancer increases with age [5-7]. 
When people aged 50 and below are referenced, 
the risk of pancreatic cancer has increased 3.5-
fold for those who are older than 65 (p<0.05). 
Many studies on pancreatic cancer have not 
revealed a significant difference between 
genders [8, 9]. In our study, gender was not 
correlated to pancreatic cancer risk (p>0.05). 
The best indicator of vitamin D level in serum 
is 25-hydroxyvitamin D3. This level is 
determined by dietary vitamin D and sun 
exposure. It is stated that serum vitamin D level 
may vary depending on age, race, BMI and 
diseases. Experimental studies suggest that the 
risk of pancreatic cancer may be reduced if the 
optimal level of serum vitamin D is achieved, 
depending on the diet or sun rays. However, 
clinical studies are inadequate; there are some 
conflicting data available, too. In one of these, 
it has been suggested that there may be an 
increased risk of pancreatic cancer with 
increased serum 25-hydroxyvitamin D3 levels. 
However, at the end of the study, the difference 
was considered to stem from the difference in 
patient-control group analysis of the studied 
population or the difference in the method used 
to measure the level of 25-hydroxyvitamin D3 
[10]. In an experimental study conducted by 
Kasiappan et al. [11] a group of mice with 
tumors were given a high-fat diet for 30 days; 
another group with a tumor was given a high-
fat diet and the vitamin D analogue seacalcitol 
(EB1089). When the two groups were 
compared, tumor growth was more than 50% in 
mice that did not receive the vitamin D 
analogue seacalcitol. In our study, the risk of 
pancreatic cancer increased by 10.2-fold in 
people with deficient serum D level compared 
to individuals with normal vitamin D level 
(p<0.05). Pre-clinical studies contain data 
which indicates that cancer risk will decrease 
with vitamin D support. Clinical studies cannot 
adequately express this. This relationship is 
maybe really weak; perhaps it may be present 
in certain cancers. 
Smoking is the most important known risk 
factor associated with pancreatic cancer. In a 
study, the risk of pancreatic cancer was found 
to be two times higher in smokers than in 
nonsmokers. It was stated that this risk would 
increase in direct proportion with the amount of 
cigarettes used and the duration of time smoked 
[12]. According to our data, there was no 
correlation between smoking and the risk of 
pancreatic cancer (p>0.05). Based on American 
Cancer Society studies, those with BMI ≥30 
had a 2.08 times greater risk of pancreatic 
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cancer than those with BMI < 25 [13]. In the 
data obtained, there was no correlation BMI and 
pancreatic cancer risk (p>0.05). Diabetes is a 
risk factor for pancreatic cancer; it can also be 
a sign of the emergence of pancreatic cancer or 
a condition that may occur after surgery. In a 
meta-analysis of 20 studies conducted by 
Everhart and Wright in 1995, the risk of 
pancreatic cancer in diabetic individuals was 
found to be 2 times more than in non-diabetic 
[1]. In the data obtained, the risk of pancreatic 
cancer in diabetic patients was found 1.2 times 
higher than in non-diabetic patients (p<0.05). 
In a study conducted with 1428 pancreatic 
cancer and 1528 healthy control groups, the rate 
of diabetes was 27.6% in people with pancreatic 
cancer, while the rate of diabetes was 9.9% in 
people in the control group. Of the patients who 
have both pancreatic cancer and diabetes, 
76.2% had newly diagnosed diabetes, which 
was significantly higher than the control group 
[14]. When non-diabetic patients were 
referenced, the risk of pancreatic cancer 
increased 19.5-fold in the presence of newly 
diagnosed type 2 diabetes (<2 years); those with 
long-term type 2 diabetes (≥2 years) had a 1.2-
fold increased risk of pancreatic cancer 
(p<0.05). 
Familial pancreatic cancer accounts for 10% of 
all patients with pancreatic cancer. In a study, 
the risk of pancreatic cancer for people in 
whose immediate family (mother, father, and 
siblings) there are at least two with pancreatic 
cancer increases the risk ten times compared 
those with no family history [15]. According to 
our data, the risk of cancer increased 4.3 times 
in patients with a family history of pancreatic 
cancer (p<0.05). 1530 pancreatic cancer 
patients and 1530 healthy individuals from the 
Pancreatic Cancer Cohort Consortium were 
evaluated in a case-control study. There was no 
significant statistical difference between those 
who had >0 or <5 grams of alcohol daily and 
those who had ≥60 grams of alcohol daily [16]. 
In another study, it was reported that consuming 
40 grams of alcohol daily increased the risk of 
pancreatic cancer 1.45 times, and that it could 
increase up to 1.62 times [17]. The results from 
these studies are contradictory. In our study, 
there was no correlation between alcohol use 
and the risk of pancreatic cancer (p>0.05). 
Research has shown that pancreatic cancer is 
more common in people living in urban areas 
with low socioeconomic condition. According 
to our data, no relationship was found between 
the place of residence and the risk of pancreatic 
cancer (p>0.05). Four percent of patients with 
chronic pancreatitis are believed to develop 
pancreatic cancer [18]. If a person has a history 
of familial pancreatitis, the risk increases 50-60 
times [19]. In our study, there was no 
correlation between the risk of chronic 
pancreatitis and pancreatic cancer (p>0.05). 
The International Agency for Research on 
Cancer classifies the helicobacter pylori as a 
proven carcinogen. In four contemporary 
studies conducted, it was iterated that there is a 
possible relationship between pancreatic cancer 
and helicobacter pylori, however further studies 
are needed [20]. According to our data, there 
was no correlation between helicobacter pylori 
and pancreatic cancer risk (p>0.05). The 
International Agency for Research on Cancer 
has proposed that foods containing folate may 
be protective against pancreatic cancer [21]. In 
a study evaluating 14 prospective cohort studies 
that involves 319716 men and 542948 women, 
the relationship between folate use and 
pancreatic cancer was investigated. Over 7-20 
years after the study, 2195 pancreatic cancers 
were identified. There was no correlation 
between folate intake and pancreatic cancer risk 
when the 15% quartile of the highest folate 
intake diet and 15% quartile of the lowest folate 
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intake diet were compared [22]. In the current 
literature, inconsistent findings have been 
observed between the amount of folate in the 
diet and the level of serum folate and the risk of 
pancreatic cancer. In the data obtained, no 
correlation between folic acid level and 
pancreatic cancer risk (p>0.05) was found. 
In a study conducted on blood types with 224 
patients who have pancreatic cancer, the risk 
was 1.5 times higher in individuals with blood 
type B than in individuals with other blood 
types; the risk was lower in individuals with 0 
type blood [23]. In our study, there was no 
correlation between ABO blood types and 
pancreatic cancer risk (p>0.05). It has been 
investigated whether there is any difference in 
pancreatic cancer risk based on Rh status or not. 
According to the statistical analysis, the risk of 
pancreatic cancer in Rh antigen negative people 
was 70% less (p<0.05). Given the differences 
in distribution of ABO and Rh blood types of 
people living all over the world and current 
studies concerning blood types, further studies 
are needed to determine whether there is a link 
between blood types and pancreatic cancer risk. 
When 13 community-based studies were 
examined, the risk of pancreatic cancer in 
atopic/allergic individuals was 30% less [24]. 
Studies examining the relationship between 
pancreatic cancer and atopy/allergy suggest that 
there is need for further studies. According to 
our data, there was no significant association 
between atopy/allergy and pancreatic cancer 
risk (p>0.05). A study shows that 
cholecystectomy increased the risk of 
pancreatic cancer by 23% and gastrectomy by 
50% [25, 26]. In our study, there was no relation 
between the risk of pancreatic cancer and 
cholecystectomy and/or gastrectomy (p>0.05). 
In the current literature, the relationship 
between cholecystectomy or gastrectomy and 
the risk of pancreatic cancer is not clear enough. 
The limitation of this study is that it is case-
controlled and cross-sectional. Therefore, the 
results may suggest that vitamin D deficiency is 
more common in patients with pancreatic 
cancer, but we cannot clearly predict the 
increased risk of pancreatic cancer in cases of 
vitamin D deficiency. Smoking is a proven risk 
factor for pancreatic cancer, but this was not 
demonstrated in our study. On the other hand, a 
similar situation applies to the relationship 
between Rh status and pancreatic cancer risk. 
We cannot expressly conclude that the risk of 
pancreatic cancer is reduced in people with Rh 
antigen negative. A population-based follow-up 
study is required for more reliable results. This 
article may contribute to the following 
population-based studies.  
The main problem with pancreatic cancer is that 
the disease cannot be detected early; when 
diagnosed, the disease is often at an advanced 
stage. Because the survival rate is low and that 
diagnosis cannot be made in the early stages of 
pancreatic cancer, primary prevention is 
important. Therefore, identification of risk 




Determination of pancreatic cancer risk factors, 
organization of imaging and screening 
programs for high-risk people can provide early 
diagnosis of the disease and prolong survival. 
Population-based studies are needed to reveal 
pancreatic cancer risk factors. 
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